References
- Fidel PL, Jr. Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C albicans. Clin Microbiol Rev 1999; 12: 80–96.
- Pfaller MA, Diekema DJ, Gibbs DL, . Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735–1745.
- Patterson TF, Kirkpatrick WR, Revankar SG, . Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol 1996; 34: 3237–3239.
- Patterson TF, Revankar SG, Kirkpatrick WR, . Simple method for detecting fluconazole-resistant yeasts with chromogenic agar. J Clin Microbiol 1996; 34: 1794–1797.
- CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard – 3rd. CLSI document M27-A3. Wayne PA: Clinical and Laboratory Standards Institute; 2008.
- Bautista-Munoz C, Boldo XM, Villa-Tanaca L, Hernandez-Rodriguez C. Identification of Candida spp. by randomly amplified polymorphic DNA analysis and differentiation between Candida albicans and Candida dubliniensis by direct PCR methods. J Clin Microbiol 2003; 41:414–420.
- Becker K, Badehorn D, Deiwick S, Peters G, Fegeler W. Molecular genotyping of Candida species with special respect to Candida (To-rulopsis) glabrata strains by arbitrarily primed PCR. J Med Microbiol 2000;49:575–581.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–408.
- Tsai HF, Krol AA, Sarti KE, Bennett JE. Candida glabrata PDR1, a tran-scriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother 2006; 50: 1384–1392.